Department of Pediatrics, Section of Neurology, University of Colorado, Aurora CO, USA.
Semin Fetal Neonatal Med. 2011 Dec;16(6):355-8. doi: 10.1016/j.siny.2011.07.004. Epub 2011 Aug 5.
In rare diseases, wherein the conduct of randomized controlled clinical trials (RCTs) is challenging, cohort studies can offer important, and, in certain instances, high quality (e.g. the prospective inception cohort study) evidence on relationships among risk factors, treatments, and outcomes. The objective of this perspective article is to provide an overview of salient issues in the design and application of institution-based prospective inception cohort studies in neonatal rare disease research, with emphasis on quality assurance measures. Rigorous implementation of the prospective inception cohort study is challenging, and application to neonates renders it even more difficult. However, when performed collaboratively among institutions employing uniform methods and quality assurance mechanisms, institution-based prospective inception cohort studies can provide optimal observational evidence to inform the design and execution of RCTs in this special pediatric population.
在罕见病中,开展随机对照临床试验(RCT)具有挑战性,队列研究可以提供关于风险因素、治疗方法和结果之间关系的重要证据,在某些情况下,其证据质量还很高(例如前瞻性起始队列研究)。本文观点的目的是概述新生儿罕见病研究中基于机构的前瞻性起始队列研究设计和应用中的突出问题,并重点介绍质量保证措施。严格实施前瞻性起始队列研究具有挑战性,而将其应用于新生儿则更加困难。然而,当在采用统一方法和质量保证机制的机构之间合作开展时,基于机构的前瞻性起始队列研究可以为优化观察性证据提供支持,为这一特殊儿科人群的 RCT 设计和实施提供信息。